Idramantone | CAS#20098-14-0 | immunostimulant

Idramantone
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584506

CAS#: 20098-14-0

Description: Idramantone is an immunostimulant, a derivative of adamantine, and used in the treatment of pulmonary tuberculosis patients.

Chemical Structure

Idramantone

CAS# 20098-14-0

Instruction

Theoretical Analysis

MedKoo Cat#: 584506
Name: Idramantone
CAS#: 20098-14-0
Chemical Formula: C10H14O2
Exact Mass: 166.10
Molecular Weight: 166.220
Elemental Analysis: C, 72.26; H, 8.49; O, 19.25

Price and Availability

Size	Price	Availability
5g	USD 275	2 Weeks
10g	USD 450	2 Weeks
25g	USD 750	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Idramantone; Kemantane

IUPAC/Chemical Name: 5-Hydroxy-2-adamantanone

InChi Key: TZBDEVBNMSLVKT-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H14O2/c11-9-7-1-6-2-8(9)5-10(12,3-6)4-7/h6-8,12H,1-5H2

SMILES Code: O=C1C2CC3CC(C2)(O)CC1C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 166.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Boĭko SS, Zherdev VP, Kisliak NA, Piatin BM, Klimova NV, Glan PV, Dvorianinov AA. [Interspecific differences in kemantan pharmacokinetics]. Eksp Klin Farmakol. 1994 Nov-Dec;57(6):48-50. Russian. PubMed PMID: 7756963.

2: Boĭko SS, Zherdev VP, Kisliak NA. [The clinical pharmacokinetics of kemantane]. Farmakol Toksikol. 1991 Jan-Feb;54(1):57-9. Russian. PubMed PMID: 1860503.

3: Man'ko VM, Pinegin BV, Rudneva TB, Zavgorodniĭ SG, Blagonravova OL, Gadzhiev RI, Artsimovich NG. [The effect of kemantane on T-helpers and T-suppressors]. Zh Mikrobiol Epidemiol Immunobiol. 1991 Sep;(9):66-7. Russian. PubMed PMID: 1836926.

4: Boĭko SS, Zherdev VP, Dvorianinov AA, Janku I, Buchar E. [Kemantane pharmacokinetics in rats]. Biull Eksp Biol Med. 1990 Nov;110(11):501-3. Russian. PubMed PMID: 2083333.

5: Man'ko VM, Pinegin BV, Rudneva TB, Blagonravova OL, Artsimovich NG, Gadzhiev RI. [The mitostatic and lymphotoxic action of kemantane and its effect on B-suppressors]. Zh Mikrobiol Epidemiol Immunobiol. 1991 Jun;(6):63-5. Russian. PubMed PMID: 1832260.

6: Kossii NV, Khomenko IS, Gergert VIa. [Treatment of immunodeficient conditions caused by viral infection with the Soviet immunomodulator kemantan in patients with pulmonary tuberculosis]. Probl Tuberk. 1991;(6):23-6. Russian. PubMed PMID: 1780303.

7: Rekalova EM. [The immunomodulator kemantan in the treatment of patients with exacerbated chronic obstructive bronchitis]. Lik Sprava. 1992 Apr;(4):73-6. Russian. PubMed PMID: 1441384.

8: Kovalev IE, Shipulina NV. Effect of adamantanone derivative possessing anti-HIV properties on the redox processes in the cytochrome P-450 system. Dokl Biochem Biophys. 2001 May-Jun;378:210-3. PubMed PMID: 11712183.

Your view history

Idramantone featured